PALATIN TECHNOLOGIES INC (PTN)
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Palatin Technologies, Inc.
- 17.4%
- 295.4K
- 7.36
Float 1.69M · Signal8 dilution snapshot · Nov 16, 2026
The cost to borrow PTN shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 48.3%
- 2.2K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 295.4K sh |
| Oct 15, 2026 | 332.2K sh |
| Sep 30, 2026 | 364.9K sh |
| Sep 15, 2026 | 361.2K sh |
| Aug 31, 2026 | 345.5K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 30, 2026 | 2.2K sh |
| Oct 23, 2026 | 121 sh |
| Oct 22, 2026 | 121 sh |
| Oct 21, 2026 | 121 sh |
| Oct 20, 2026 | 51 sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 48.3% |
| Nov 16, 2026 | 74.5% |
| Nov 13, 2026 | 52.9% |
| Nov 12, 2026 | 84.7% |
| Nov 11, 2026 | 43.3% |
130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for PTN: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 295,427 PTN shares were sold short (17.45% of a 1.69M-share float, 7.36 days to cover).